Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julius Popp

Showing results (111-120 of 156) with videos related to

Pageof 16
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 14, 2022
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiologyAurore Delvenne, Johan Gobom, Betty Tijms, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's diseaseEleonora M Vromen, Senne B Lageman, Johan Gobom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 12, 2019
Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrumIsabelle Bos, Stephanie Vos, Frans Verhey, et al.
Medrxiv : the Preprint Server for Health Sciences|November 11, 2020
Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's diseasePieter Jelle Visser, Lianne M Reus, Johan Gobom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2024
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's diseaseAurore Delvenne, Johan Gobom, Suzanne E Schindler, et al.
Fluids and Barriers of the CNS|July 17, 2024
Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studiesAurore Delvenne, Charysse Vandendriessche, Johan Gobom, et al.
Molecular Neurodegeneration|March 29, 2022
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's diseasePieter Jelle Visser, Lianne M Reus, Johan Gobom, et al.
Computers in Biology and Medicine|May 18, 2024
Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's diseaseAlicia Gómez-Pascual, Talel Naccache, Jin Xu, et al.
Human Molecular Genetics|July 17, 2014
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's diseaseAlfredo Ramirez, Wiesje M van der Flier, Christine Herold, et al.
Molecular Psychiatry|February 17, 2022
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammationAlexander Neumann, Fahri Küçükali, Isabelle Bos, et al.
Pageof 16

Showing results (111-120 of 156) with videos related to

Sort By:
Pageof 16
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 14, 2022
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiologyAurore Delvenne, Johan Gobom, Betty Tijms, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's diseaseEleonora M Vromen, Senne B Lageman, Johan Gobom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 12, 2019
Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrumIsabelle Bos, Stephanie Vos, Frans Verhey, et al.
Medrxiv : the Preprint Server for Health Sciences|November 11, 2020
Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's diseasePieter Jelle Visser, Lianne M Reus, Johan Gobom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2024
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's diseaseAurore Delvenne, Johan Gobom, Suzanne E Schindler, et al.
Fluids and Barriers of the CNS|July 17, 2024
Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studiesAurore Delvenne, Charysse Vandendriessche, Johan Gobom, et al.
Molecular Neurodegeneration|March 29, 2022
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's diseasePieter Jelle Visser, Lianne M Reus, Johan Gobom, et al.
Computers in Biology and Medicine|May 18, 2024
Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's diseaseAlicia Gómez-Pascual, Talel Naccache, Jin Xu, et al.
Human Molecular Genetics|July 17, 2014
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's diseaseAlfredo Ramirez, Wiesje M van der Flier, Christine Herold, et al.
Molecular Psychiatry|February 17, 2022
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammationAlexander Neumann, Fahri Küçükali, Isabelle Bos, et al.
Pageof 16